HomeMember NewsHealthcareAurobindo Pharma USA Breaks Ground on 567K Sq. ft. Facility

Aurobindo Pharma USA Breaks Ground on 567K Sq. ft. Facility

AUROBINDO PHARMA USA BREAKS GROUND ON 567,000 SQUARE FOOT FACILITY NEW U.S. CORPORATE HEADQUARTERS CAMPUS IN EAST  WINDSOR TOWNSHIP

EAST WINDSOR TOWNSHIP.   East Windsor Township Mayor Janice S. Mironov, joined by Deputy Mayor Peter Yeager and Council Members Denise Daniels and John Zoller, as well as Robert Cunard, CEO, Aurobindo USA and P.V. Ramprasad Reddy, Chairperson, Aurobindo, held a groundbreaking for the Aurobindo USA new 567,000 square foot East Windsor facility, located on Windsor Center Drive across from Route 133 along the Township Route 571

Pharmaceutical Company Aurobindo USA  has announced that this 90 acre East Windsor campus is to be the new site of their U.S. Corporate Headquarters.  Aurobindo, an India-based pharmaceutical company, is constructing a new 567,000 square-foot pharmaceutical warehouse, distribution and manufacturing center which will generate new tax dollars and 400 to 500 new jobs when fully operational, as an expansion of the company’s New Jersey footprint.  Further, Aurobindo has now occupied as administrative offices the 43,000 square foot Patscentre building at Route 571 (Princeton Hightstown Road and Route 535 (Old Trenton Road), and by year end will have relocated to this building an additional total of 110 employees.  The Patscentre building designed by renowned British architect Sir Richard Rogers who is best known for the Pompidou Cultural Centre in Paris was originally occupied by P.A. Technology when it opened in 1984

Mayor Janice S. Mironov stated, “This is an exciting day as the size and scope of this facility marks a significant investment by Aurobindo in East Windsor Township, generating substantial local tax dollars and several hundred new jobs for our area.

Global company Aurobindo’s selection of East Windsor Township as its new U.S. corporate headquarters and the undertaking of this major new facility underscores once again the tremendous attraction of the Township for high-tech, high growth research and development pharmaceutical-related companies.  Aurobindo is another great fit within our Einstein’s Alley designation and vision, expanding further the burgeoning pharmaceutical and biotech community here in East Windsor.”  Mayor Mironov continued, “We are gratified that Aurobindo has identified East Windsor and this prime strategic location, connecting directly to East Windsor NJ Turnpike Exit 8 via Route 133, to be their choice to grow and advance their pharmaceutical company.”

Aurobindo USA Chief Executive Officer Robert Cunard stated, “Aurobindo is very happy to reach this milestone in our growth in New Jersey, and our major expansion to East Windsor.  We have appreciated the valuable assistance and guidance of the Mayor and her team in moving forward with our business plans and look forward to becoming part of the East Windsor business community as we make this great site our new US corporate home.”

Headquartered in HITEC City, Hyderabad, India, founded in 1986 and becoming a public company in 1992, Aurobindo has business operations in more than 125 countries around the world.  Aurobindo is a global pharmaceutical company with a broad portfolio of generic drugs that includes more than 125 product families and 450 individual product packages.  Aurobindo USA is a generic pharmaceutical manufacturer and distributor and is a wholly owned subsidiary of Aurobindo Pharma Limited, a leading generic pharmaceutical company based in India.

The expansion of Aurobindo into East Windsor Township comes at a time of rapid growth for the company.  In the past 12 months, Aurobindo has earned the highest number of final Abbreviated New Drug Application FDA approvals among all competitors, and ranks 8th among all generic pharmaceutical companies. Most recently, Aurobindo announced that the Food and Drug Administration had approved its generic version of Tricor, a drug which treats high cholesterol and high triglycerides.  The product had estimated U.S. sales of about $412.1 million for the twelve months ended March 2016, according to IMS Health.

Comments

comments

FOLLOW US ON:
Tech Ed: From the Ne
Energy Keeps Passing
Rate This Article:
NO COMMENTS

Sorry, the comment form is closed at this time.